Intellipharmaceutics International @ The Next Biggest Winner - $IPCI

The Next Biggest Winner helps both savvy and novice investors find the next biggest winning stock. In this interview, Shameze Rampertab of Intellipharmaceutics International (NASDAQ: IPCI) reports on the company and its progress. Mr. Rampertab joined Intellipharmaceutics in November 2010. He is a chartered accountant (CA) since 1994, brings public company experience to Intellipharmaceutics, having previously served as the Director, Finance and Secretary-Treasurer for then-public Drug Royalty Corp. Mr. Rampertab also served as health sciences and biotechnology analyst at several investment banking firms including Canaccord Capital, and was until recently a Partner, Healthcare Investment Banking at Loewen Ondaatje McCutcheon Limited, where he specialized in raising equity funds for life-science companies. He received an MBA from McMaster University and a BSc. from the University of Toronto and has substantial expertise with licensing and royalty deals. Mr. Rampertab is currently Chairman of the Board of Imaging Dynamics Company Ltd. (TSX: IDL).

Intellipharmaceutics is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix(TM) technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of product candidates in various stages of development, including six ANDAs under review by the FDA, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes, pain and infection.